Reference:
  1. C Baigent, A Keech, P M Kearney, and Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins.Lancet . 2005; 366: 1267-78.
  2. Connie N Hess, Robert M Clare, Megan L Neely, et al. Differential Occurrence, Profile, and Impact of First Recurrent Cardiovascular Events After an Acute Coronary Syndrome. Am Heart J. 2017;187: 194-203.
  3. Jian-Jun Li, Xin Zheng, Jie Li. Different Concept in Cholesterol Lower Therapy in Chinese Atherosclerotic Cardiovascular Disease. Med Hypotheses . 2007;69:333-7.
  4. Mei Zhang, Qian Deng, Linhong Wang, et al. Prevalence of Dyslipidemia and Achievement of Low-Density Lipoprotein Cholesterol Targets in Chinese Adults: A Nationally Representative Survey of 163,641 Adults.Int J Cardiol . 2018; 260:196-203.
  5. François Mach, Colin Baigent, Alberico L Catapano, et al. 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. Eur Heart J . 2020; 41:111-188.
  6. Emelia J Benjamin, Salim S Virani, Clifton W Callaway, et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association.Circulation . 2018;137:e67-e492. 
  7. Li Y, Zhao SP, Ye P, et al. Status of Cholesterol Goal Attainment for the Primary and Secondary Prevention of Atherosclerotic Cardiovascular Disease in Dyslipidemia Patients Receiving Lipid-Lowering Therapy: DYSIS-China Subgroup Analysis. Zhonghua Xin Xue Guan Bing Za Zhi . 2016;44:665-70.
  8. Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.Lancet . 2012;380:1995–2006.
  9. Schwartz G G, Steg P G, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018; 379:2097-2107.
  10. Sabatine M S, Giugliano R P, Keech A C, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med . 2017;376:1713-1722.
  11. Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation . 2019;139:e1082-e1143.
  12. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol . 2012;60:1581–98.
  13. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J . 2013;34:1279-1291.
  14. Atherosclerosis and Coronary Heart Disease Working Group of Chinese Society of Cardiology; Editorial Board of Chinese Journal of CardiologyChinese Expert. Consensus on Lipid Management of Very High-Risk Atherosclerotic Cardiovascular Disease Patients. Zhonghua Xin Xue Guan Ji Bing Za Zhi . 2020;48:280-286.
  15. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372: 2387⁃2397.
  16. Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol . 2014;63:2531-2540.
  17. Drazen JM, Jarcho JA, Morrissey S, Curfman GD. Cholesterol Lowering and Ezetimibe. N Engl J Med . 2008;358:1507-8.
  18. van der Graaf A, Cuffie-Jackson C, Vissers MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol . 2008;52:1421-9.
  19. Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosisregulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA . 2003;100:928–933.
  20. Naureckiene S, Ma L, Sreekumar K, et al. Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys . 2003;420:55–67.
  21. Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem . 2004;279: 48865–48875.
  22. Cholesterol Treatment Trialists’ (CTT) Collaboration; C Baigent, L Blackwell, et al. Efficacy and Safety of More Intensive Lowering of LDL Cholesterol: A Meta-Analysis of Data From 170,000 Participants in 26 Randomised Trials. Lancet . 2010;376:1670-81.